Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes

Background and Aim: The entity defined by the WHO 2017 classification as myeloid neoplasms with germinal predisposition without preexisting disorder or organ dysfunction is particularly interesting within myelodysplastic syndromes (MDS) for three main reasons: i) in myeloid disease derived from cong...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2019-11, Vol.134 (Supplement_1), p.4226-4226
Hauptverfasser: Chen-Liang, Tzu Hua, Hurtado López, Ana M, Zurdo, María, Such, Esperanza, Teruel-Montoya, Raul, Palomo, Laura, Jimenez, María-José, del Orbe Barreto, Rafael Andres, Navarro, Blanca, López Cadenas, Félix, Salido, Eduardo José, Benet, Carmen, Muiña, Begoña, de Oña, Raquel, de Haro, Nuria, Ramos, Fernando, Arnan Sangerman, Montserrat, Hernandez, Francisca Maria, Ortuño, Francisco José, Senent, Leonor, Vicente, Ana, Díez-Campelo, María, Hermosin, Maria Lourdes, Bernal Del Castillo, Teresa, Tormo, Mar, Arrizabalaga, Beatriz, Xicoy, Blanca, Cervera, José, Sole, Francesc, Sanz, Guillermo F., Jerez, Andres
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4226
container_issue Supplement_1
container_start_page 4226
container_title Blood
container_volume 134
creator Chen-Liang, Tzu Hua
Hurtado López, Ana M
Zurdo, María
Such, Esperanza
Teruel-Montoya, Raul
Palomo, Laura
Jimenez, María-José
del Orbe Barreto, Rafael Andres
Navarro, Blanca
López Cadenas, Félix
Salido, Eduardo José
Benet, Carmen
Muiña, Begoña
de Oña, Raquel
de Haro, Nuria
Ramos, Fernando
Arnan Sangerman, Montserrat
Hernandez, Francisca Maria
Ortuño, Francisco José
Senent, Leonor
Vicente, Ana
Díez-Campelo, María
Hermosin, Maria Lourdes
Bernal Del Castillo, Teresa
Tormo, Mar
Arrizabalaga, Beatriz
Xicoy, Blanca
Cervera, José
Sole, Francesc
Sanz, Guillermo F.
Jerez, Andres
description Background and Aim: The entity defined by the WHO 2017 classification as myeloid neoplasms with germinal predisposition without preexisting disorder or organ dysfunction is particularly interesting within myelodysplastic syndromes (MDS) for three main reasons: i) in myeloid disease derived from congenital bone marrow failure, therapeutic strategies (e.g., type of conditioning regimen) are defined; it is not the case within the group of young patients with MDS harbouring germinal variants, actually a group candidate for allogeneic transplantation of hematopoietic progenitors, ii) its incidence exceeds the cases secondary to congenital bone marrow failure, and iii) the implications of genetic counseling to patients and relatives are yet to be defined and have not been addressed at the time of diagnosis of MDS. Methods: Whole exome sequencing (WES) was performed on 118 tumour and 73 paired germinal DNA from patients of 16 Spanish Group of MDS (GESMD) centers, diagnosed with de novo MDS between 16-60 years old without previous organ dysfunction. WES libraries were sequenced on a HiSeq4000-NovaSeq6000-Illumina platform, mean number of reads per sample was 144,429,985 with a Phred Quality Score >30 in 94% of bases and a 100x average depth. To identify potential germline-predisposing mutations, a selection tool incorporating 279 genes associated with cause or predisposition to bone marrow failure or cancer was implemented. The analysis of the variants was carried out by means of an in house pipeline: filtering out intronic, synonymous, and those variants with minor allele frequency (MAF) in the general population >1% (ExAC, 1000 Genomes-phase3, TOPmed), and requiring the presence both in tumour and germline DNA with a VAF>37%. In 45 cases without germline material the last requirement was substituted by not being reported as somatic in COSMIC in any cancer. To determine pathogenicity we followed conservative criteria: a CADD Phred score ≥20 and to be considered deleterious in, at least, three out of six used algorithm. Results: In 118 patients, the median age at diagnosis was 47 years with the following WHO 2017 diagnoses: 12% MDS-SLD, 9% MDS-RS, 34% MDS-MLD, 30% MDS-EB, 3% MDS-del(5q), 1%MDS-U, 11% CMML. We found deleterious/pathogenic germ variants in 68 of 118 patients. Strikingly, we found a higher frequency than expected, for this specific subset, in genes not yet considered in the category of myeloid neoplasms with germline predisposition: MSH6 (n=5;4.2%),
doi_str_mv 10.1182/blood-2019-127204
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2019_127204</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497118621548</els_id><sourcerecordid>S0006497118621548</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1374-fe18c543c8aee646a4a1b65c4fd8eeb42e19147ce17876199f48ada492d229623</originalsourceid><addsrcrecordid>eNp9UUuOEzEQtRBIhIEDsPMFGlyO0x9YjSYQIs1okPhIrFqOXT0UcuzI5Qb6fhyM7oQ1qyrp1fuonhAvQb0CaPXrQ0jJV1pBV4FutDKPxAo2uq2U0uqxWCml6sp0DTwVz5h_KAVmrTcr8WeH-UjRBvkxoyc-JaZCKUqK8m7CkPzEp2C5kJOfpuhzOiIv4Lc0xgd57cdQWP6i8j2NRdpFBX_TfD6DW-KUPWaZsrzPDzbK7cTDGN1i8EbuPcZCAzl7NkyD3GLAgpnSyPKrzWRjOXvdkcuJbcEQqKDcRy72QPM-yR1G5OfiyWAD44t_80p8ef_u882H6vZ-t7-5vq0crBtTDQit25i1ay1ibWprLBzqjTODbxEPRiN0YBqH0LRNDV03mNZ6azrtte5qvb4ScNFd4nDGoT9lOto89aD6pYb-XEO_1NBfapg5by8cnIP9JMw9O8Lo5mdndKX3if7D_gsCMZbB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Chen-Liang, Tzu Hua ; Hurtado López, Ana M ; Zurdo, María ; Such, Esperanza ; Teruel-Montoya, Raul ; Palomo, Laura ; Jimenez, María-José ; del Orbe Barreto, Rafael Andres ; Navarro, Blanca ; López Cadenas, Félix ; Salido, Eduardo José ; Benet, Carmen ; Muiña, Begoña ; de Oña, Raquel ; de Haro, Nuria ; Ramos, Fernando ; Arnan Sangerman, Montserrat ; Hernandez, Francisca Maria ; Ortuño, Francisco José ; Senent, Leonor ; Vicente, Ana ; Díez-Campelo, María ; Hermosin, Maria Lourdes ; Bernal Del Castillo, Teresa ; Tormo, Mar ; Arrizabalaga, Beatriz ; Xicoy, Blanca ; Cervera, José ; Sole, Francesc ; Sanz, Guillermo F. ; Jerez, Andres</creator><creatorcontrib>Chen-Liang, Tzu Hua ; Hurtado López, Ana M ; Zurdo, María ; Such, Esperanza ; Teruel-Montoya, Raul ; Palomo, Laura ; Jimenez, María-José ; del Orbe Barreto, Rafael Andres ; Navarro, Blanca ; López Cadenas, Félix ; Salido, Eduardo José ; Benet, Carmen ; Muiña, Begoña ; de Oña, Raquel ; de Haro, Nuria ; Ramos, Fernando ; Arnan Sangerman, Montserrat ; Hernandez, Francisca Maria ; Ortuño, Francisco José ; Senent, Leonor ; Vicente, Ana ; Díez-Campelo, María ; Hermosin, Maria Lourdes ; Bernal Del Castillo, Teresa ; Tormo, Mar ; Arrizabalaga, Beatriz ; Xicoy, Blanca ; Cervera, José ; Sole, Francesc ; Sanz, Guillermo F. ; Jerez, Andres</creatorcontrib><description>Background and Aim: The entity defined by the WHO 2017 classification as myeloid neoplasms with germinal predisposition without preexisting disorder or organ dysfunction is particularly interesting within myelodysplastic syndromes (MDS) for three main reasons: i) in myeloid disease derived from congenital bone marrow failure, therapeutic strategies (e.g., type of conditioning regimen) are defined; it is not the case within the group of young patients with MDS harbouring germinal variants, actually a group candidate for allogeneic transplantation of hematopoietic progenitors, ii) its incidence exceeds the cases secondary to congenital bone marrow failure, and iii) the implications of genetic counseling to patients and relatives are yet to be defined and have not been addressed at the time of diagnosis of MDS. Methods: Whole exome sequencing (WES) was performed on 118 tumour and 73 paired germinal DNA from patients of 16 Spanish Group of MDS (GESMD) centers, diagnosed with de novo MDS between 16-60 years old without previous organ dysfunction. WES libraries were sequenced on a HiSeq4000-NovaSeq6000-Illumina platform, mean number of reads per sample was 144,429,985 with a Phred Quality Score &gt;30 in 94% of bases and a 100x average depth. To identify potential germline-predisposing mutations, a selection tool incorporating 279 genes associated with cause or predisposition to bone marrow failure or cancer was implemented. The analysis of the variants was carried out by means of an in house pipeline: filtering out intronic, synonymous, and those variants with minor allele frequency (MAF) in the general population &gt;1% (ExAC, 1000 Genomes-phase3, TOPmed), and requiring the presence both in tumour and germline DNA with a VAF&gt;37%. In 45 cases without germline material the last requirement was substituted by not being reported as somatic in COSMIC in any cancer. To determine pathogenicity we followed conservative criteria: a CADD Phred score ≥20 and to be considered deleterious in, at least, three out of six used algorithm. Results: In 118 patients, the median age at diagnosis was 47 years with the following WHO 2017 diagnoses: 12% MDS-SLD, 9% MDS-RS, 34% MDS-MLD, 30% MDS-EB, 3% MDS-del(5q), 1%MDS-U, 11% CMML. We found deleterious/pathogenic germ variants in 68 of 118 patients. Strikingly, we found a higher frequency than expected, for this specific subset, in genes not yet considered in the category of myeloid neoplasms with germline predisposition: MSH6 (n=5;4.2%), ATR (n=5;4.2%), ERCC6L2 (n=4;3.4%), PMS2 (n=2; 1.6%), MLH1 (n=3;3.5%), HCLS1 (n=2;1.7%), ITGB3 (n=2;1.7%), LYST (n=4; 3.4%), SAMD9 (n=1;0.8%), MSH2(n=1;0.8%). In genes already considered in the category of myeloid neoplasms with germline predisposition: MPL (n=2;1.7%), DDX41 (n= 2;1.7%), RUNX1 (n=1; 0.8%), ANKRD26 (n=1;0.8%). We also detected 10 cases with deleterious germline variants in genes related to Fanconi anemia (BRIP1, FANCC, FANCD2, FANCG, FANCM, SLX4, XRCC2, RAD51C and BRCA2), 2 cases with a germline variant in a Shwachman-Diamond gene DNAJC21 (1.7%), and 3 cases with germline variant in a telomere biology gene (RTEL1, CTC1 and TERT). We then focused on the characterization of the variants found in 5 genes not considered to date as predisposing to MDS: MSH6, MSH2, MLH1, ATR and PMS2 involved in the instability of microsatellites and whose alteration determines genomic instability and predisposition to a different number of solid tumors. The frequency of patients carrying these variants (13.5%) is much higher than the frequency of DDX41 (1.7%) or CEBPA (not found in our cohort), the two genes currently considered in the category with germline predisposition without a preexisting disorder or organ dysfunction. The sixteen patients carrying these mutations were characterized by a median age of 47 (16-60) years with the following diagnoses, 33% MDS-MLD, 27% MDS-EB1 and 40% CMML, presenting up to 40% with decrease cellularity in the bone marrow. Conclusions: We describe, for the first time, a high frequency of germinal variants in genes that drive genomic instability by modulating the microsatellite pathway, in young adults diagnosed with MDS without previous organ dysfunction. Their frequency and high pathogenicity index warrant functional validation experiments and pose them as potential candidates to be included in future classifications and to be considered in clinical, therapeutic and genetic counseling strategies. [Display omitted] Díez-Campelo:Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene Corporation: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Sanz:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Helsinn Healthcare: Membership on an entity's Board of Directors or advisory committees, Research Funding; Onconova: Membership on an entity's Board of Directors or advisory committees, Research Funding; Hoffman - La Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Boehringer-Ingelheim: Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen - Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Jerez:Novartis: Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2019-127204</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2019-11, Vol.134 (Supplement_1), p.4226-4226</ispartof><rights>2019 American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Chen-Liang, Tzu Hua</creatorcontrib><creatorcontrib>Hurtado López, Ana M</creatorcontrib><creatorcontrib>Zurdo, María</creatorcontrib><creatorcontrib>Such, Esperanza</creatorcontrib><creatorcontrib>Teruel-Montoya, Raul</creatorcontrib><creatorcontrib>Palomo, Laura</creatorcontrib><creatorcontrib>Jimenez, María-José</creatorcontrib><creatorcontrib>del Orbe Barreto, Rafael Andres</creatorcontrib><creatorcontrib>Navarro, Blanca</creatorcontrib><creatorcontrib>López Cadenas, Félix</creatorcontrib><creatorcontrib>Salido, Eduardo José</creatorcontrib><creatorcontrib>Benet, Carmen</creatorcontrib><creatorcontrib>Muiña, Begoña</creatorcontrib><creatorcontrib>de Oña, Raquel</creatorcontrib><creatorcontrib>de Haro, Nuria</creatorcontrib><creatorcontrib>Ramos, Fernando</creatorcontrib><creatorcontrib>Arnan Sangerman, Montserrat</creatorcontrib><creatorcontrib>Hernandez, Francisca Maria</creatorcontrib><creatorcontrib>Ortuño, Francisco José</creatorcontrib><creatorcontrib>Senent, Leonor</creatorcontrib><creatorcontrib>Vicente, Ana</creatorcontrib><creatorcontrib>Díez-Campelo, María</creatorcontrib><creatorcontrib>Hermosin, Maria Lourdes</creatorcontrib><creatorcontrib>Bernal Del Castillo, Teresa</creatorcontrib><creatorcontrib>Tormo, Mar</creatorcontrib><creatorcontrib>Arrizabalaga, Beatriz</creatorcontrib><creatorcontrib>Xicoy, Blanca</creatorcontrib><creatorcontrib>Cervera, José</creatorcontrib><creatorcontrib>Sole, Francesc</creatorcontrib><creatorcontrib>Sanz, Guillermo F.</creatorcontrib><creatorcontrib>Jerez, Andres</creatorcontrib><title>Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes</title><title>Blood</title><description>Background and Aim: The entity defined by the WHO 2017 classification as myeloid neoplasms with germinal predisposition without preexisting disorder or organ dysfunction is particularly interesting within myelodysplastic syndromes (MDS) for three main reasons: i) in myeloid disease derived from congenital bone marrow failure, therapeutic strategies (e.g., type of conditioning regimen) are defined; it is not the case within the group of young patients with MDS harbouring germinal variants, actually a group candidate for allogeneic transplantation of hematopoietic progenitors, ii) its incidence exceeds the cases secondary to congenital bone marrow failure, and iii) the implications of genetic counseling to patients and relatives are yet to be defined and have not been addressed at the time of diagnosis of MDS. Methods: Whole exome sequencing (WES) was performed on 118 tumour and 73 paired germinal DNA from patients of 16 Spanish Group of MDS (GESMD) centers, diagnosed with de novo MDS between 16-60 years old without previous organ dysfunction. WES libraries were sequenced on a HiSeq4000-NovaSeq6000-Illumina platform, mean number of reads per sample was 144,429,985 with a Phred Quality Score &gt;30 in 94% of bases and a 100x average depth. To identify potential germline-predisposing mutations, a selection tool incorporating 279 genes associated with cause or predisposition to bone marrow failure or cancer was implemented. The analysis of the variants was carried out by means of an in house pipeline: filtering out intronic, synonymous, and those variants with minor allele frequency (MAF) in the general population &gt;1% (ExAC, 1000 Genomes-phase3, TOPmed), and requiring the presence both in tumour and germline DNA with a VAF&gt;37%. In 45 cases without germline material the last requirement was substituted by not being reported as somatic in COSMIC in any cancer. To determine pathogenicity we followed conservative criteria: a CADD Phred score ≥20 and to be considered deleterious in, at least, three out of six used algorithm. Results: In 118 patients, the median age at diagnosis was 47 years with the following WHO 2017 diagnoses: 12% MDS-SLD, 9% MDS-RS, 34% MDS-MLD, 30% MDS-EB, 3% MDS-del(5q), 1%MDS-U, 11% CMML. We found deleterious/pathogenic germ variants in 68 of 118 patients. Strikingly, we found a higher frequency than expected, for this specific subset, in genes not yet considered in the category of myeloid neoplasms with germline predisposition: MSH6 (n=5;4.2%), ATR (n=5;4.2%), ERCC6L2 (n=4;3.4%), PMS2 (n=2; 1.6%), MLH1 (n=3;3.5%), HCLS1 (n=2;1.7%), ITGB3 (n=2;1.7%), LYST (n=4; 3.4%), SAMD9 (n=1;0.8%), MSH2(n=1;0.8%). In genes already considered in the category of myeloid neoplasms with germline predisposition: MPL (n=2;1.7%), DDX41 (n= 2;1.7%), RUNX1 (n=1; 0.8%), ANKRD26 (n=1;0.8%). We also detected 10 cases with deleterious germline variants in genes related to Fanconi anemia (BRIP1, FANCC, FANCD2, FANCG, FANCM, SLX4, XRCC2, RAD51C and BRCA2), 2 cases with a germline variant in a Shwachman-Diamond gene DNAJC21 (1.7%), and 3 cases with germline variant in a telomere biology gene (RTEL1, CTC1 and TERT). We then focused on the characterization of the variants found in 5 genes not considered to date as predisposing to MDS: MSH6, MSH2, MLH1, ATR and PMS2 involved in the instability of microsatellites and whose alteration determines genomic instability and predisposition to a different number of solid tumors. The frequency of patients carrying these variants (13.5%) is much higher than the frequency of DDX41 (1.7%) or CEBPA (not found in our cohort), the two genes currently considered in the category with germline predisposition without a preexisting disorder or organ dysfunction. The sixteen patients carrying these mutations were characterized by a median age of 47 (16-60) years with the following diagnoses, 33% MDS-MLD, 27% MDS-EB1 and 40% CMML, presenting up to 40% with decrease cellularity in the bone marrow. Conclusions: We describe, for the first time, a high frequency of germinal variants in genes that drive genomic instability by modulating the microsatellite pathway, in young adults diagnosed with MDS without previous organ dysfunction. Their frequency and high pathogenicity index warrant functional validation experiments and pose them as potential candidates to be included in future classifications and to be considered in clinical, therapeutic and genetic counseling strategies. [Display omitted] Díez-Campelo:Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene Corporation: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Sanz:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Helsinn Healthcare: Membership on an entity's Board of Directors or advisory committees, Research Funding; Onconova: Membership on an entity's Board of Directors or advisory committees, Research Funding; Hoffman - La Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Boehringer-Ingelheim: Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen - Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Jerez:Novartis: Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees.</description><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9UUuOEzEQtRBIhIEDsPMFGlyO0x9YjSYQIs1okPhIrFqOXT0UcuzI5Qb6fhyM7oQ1qyrp1fuonhAvQb0CaPXrQ0jJV1pBV4FutDKPxAo2uq2U0uqxWCml6sp0DTwVz5h_KAVmrTcr8WeH-UjRBvkxoyc-JaZCKUqK8m7CkPzEp2C5kJOfpuhzOiIv4Lc0xgd57cdQWP6i8j2NRdpFBX_TfD6DW-KUPWaZsrzPDzbK7cTDGN1i8EbuPcZCAzl7NkyD3GLAgpnSyPKrzWRjOXvdkcuJbcEQqKDcRy72QPM-yR1G5OfiyWAD44t_80p8ef_u882H6vZ-t7-5vq0crBtTDQit25i1ay1ibWprLBzqjTODbxEPRiN0YBqH0LRNDV03mNZ6azrtte5qvb4ScNFd4nDGoT9lOto89aD6pYb-XEO_1NBfapg5by8cnIP9JMw9O8Lo5mdndKX3if7D_gsCMZbB</recordid><startdate>20191113</startdate><enddate>20191113</enddate><creator>Chen-Liang, Tzu Hua</creator><creator>Hurtado López, Ana M</creator><creator>Zurdo, María</creator><creator>Such, Esperanza</creator><creator>Teruel-Montoya, Raul</creator><creator>Palomo, Laura</creator><creator>Jimenez, María-José</creator><creator>del Orbe Barreto, Rafael Andres</creator><creator>Navarro, Blanca</creator><creator>López Cadenas, Félix</creator><creator>Salido, Eduardo José</creator><creator>Benet, Carmen</creator><creator>Muiña, Begoña</creator><creator>de Oña, Raquel</creator><creator>de Haro, Nuria</creator><creator>Ramos, Fernando</creator><creator>Arnan Sangerman, Montserrat</creator><creator>Hernandez, Francisca Maria</creator><creator>Ortuño, Francisco José</creator><creator>Senent, Leonor</creator><creator>Vicente, Ana</creator><creator>Díez-Campelo, María</creator><creator>Hermosin, Maria Lourdes</creator><creator>Bernal Del Castillo, Teresa</creator><creator>Tormo, Mar</creator><creator>Arrizabalaga, Beatriz</creator><creator>Xicoy, Blanca</creator><creator>Cervera, José</creator><creator>Sole, Francesc</creator><creator>Sanz, Guillermo F.</creator><creator>Jerez, Andres</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20191113</creationdate><title>Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes</title><author>Chen-Liang, Tzu Hua ; Hurtado López, Ana M ; Zurdo, María ; Such, Esperanza ; Teruel-Montoya, Raul ; Palomo, Laura ; Jimenez, María-José ; del Orbe Barreto, Rafael Andres ; Navarro, Blanca ; López Cadenas, Félix ; Salido, Eduardo José ; Benet, Carmen ; Muiña, Begoña ; de Oña, Raquel ; de Haro, Nuria ; Ramos, Fernando ; Arnan Sangerman, Montserrat ; Hernandez, Francisca Maria ; Ortuño, Francisco José ; Senent, Leonor ; Vicente, Ana ; Díez-Campelo, María ; Hermosin, Maria Lourdes ; Bernal Del Castillo, Teresa ; Tormo, Mar ; Arrizabalaga, Beatriz ; Xicoy, Blanca ; Cervera, José ; Sole, Francesc ; Sanz, Guillermo F. ; Jerez, Andres</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1374-fe18c543c8aee646a4a1b65c4fd8eeb42e19147ce17876199f48ada492d229623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen-Liang, Tzu Hua</creatorcontrib><creatorcontrib>Hurtado López, Ana M</creatorcontrib><creatorcontrib>Zurdo, María</creatorcontrib><creatorcontrib>Such, Esperanza</creatorcontrib><creatorcontrib>Teruel-Montoya, Raul</creatorcontrib><creatorcontrib>Palomo, Laura</creatorcontrib><creatorcontrib>Jimenez, María-José</creatorcontrib><creatorcontrib>del Orbe Barreto, Rafael Andres</creatorcontrib><creatorcontrib>Navarro, Blanca</creatorcontrib><creatorcontrib>López Cadenas, Félix</creatorcontrib><creatorcontrib>Salido, Eduardo José</creatorcontrib><creatorcontrib>Benet, Carmen</creatorcontrib><creatorcontrib>Muiña, Begoña</creatorcontrib><creatorcontrib>de Oña, Raquel</creatorcontrib><creatorcontrib>de Haro, Nuria</creatorcontrib><creatorcontrib>Ramos, Fernando</creatorcontrib><creatorcontrib>Arnan Sangerman, Montserrat</creatorcontrib><creatorcontrib>Hernandez, Francisca Maria</creatorcontrib><creatorcontrib>Ortuño, Francisco José</creatorcontrib><creatorcontrib>Senent, Leonor</creatorcontrib><creatorcontrib>Vicente, Ana</creatorcontrib><creatorcontrib>Díez-Campelo, María</creatorcontrib><creatorcontrib>Hermosin, Maria Lourdes</creatorcontrib><creatorcontrib>Bernal Del Castillo, Teresa</creatorcontrib><creatorcontrib>Tormo, Mar</creatorcontrib><creatorcontrib>Arrizabalaga, Beatriz</creatorcontrib><creatorcontrib>Xicoy, Blanca</creatorcontrib><creatorcontrib>Cervera, José</creatorcontrib><creatorcontrib>Sole, Francesc</creatorcontrib><creatorcontrib>Sanz, Guillermo F.</creatorcontrib><creatorcontrib>Jerez, Andres</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen-Liang, Tzu Hua</au><au>Hurtado López, Ana M</au><au>Zurdo, María</au><au>Such, Esperanza</au><au>Teruel-Montoya, Raul</au><au>Palomo, Laura</au><au>Jimenez, María-José</au><au>del Orbe Barreto, Rafael Andres</au><au>Navarro, Blanca</au><au>López Cadenas, Félix</au><au>Salido, Eduardo José</au><au>Benet, Carmen</au><au>Muiña, Begoña</au><au>de Oña, Raquel</au><au>de Haro, Nuria</au><au>Ramos, Fernando</au><au>Arnan Sangerman, Montserrat</au><au>Hernandez, Francisca Maria</au><au>Ortuño, Francisco José</au><au>Senent, Leonor</au><au>Vicente, Ana</au><au>Díez-Campelo, María</au><au>Hermosin, Maria Lourdes</au><au>Bernal Del Castillo, Teresa</au><au>Tormo, Mar</au><au>Arrizabalaga, Beatriz</au><au>Xicoy, Blanca</au><au>Cervera, José</au><au>Sole, Francesc</au><au>Sanz, Guillermo F.</au><au>Jerez, Andres</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes</atitle><jtitle>Blood</jtitle><date>2019-11-13</date><risdate>2019</risdate><volume>134</volume><issue>Supplement_1</issue><spage>4226</spage><epage>4226</epage><pages>4226-4226</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Background and Aim: The entity defined by the WHO 2017 classification as myeloid neoplasms with germinal predisposition without preexisting disorder or organ dysfunction is particularly interesting within myelodysplastic syndromes (MDS) for three main reasons: i) in myeloid disease derived from congenital bone marrow failure, therapeutic strategies (e.g., type of conditioning regimen) are defined; it is not the case within the group of young patients with MDS harbouring germinal variants, actually a group candidate for allogeneic transplantation of hematopoietic progenitors, ii) its incidence exceeds the cases secondary to congenital bone marrow failure, and iii) the implications of genetic counseling to patients and relatives are yet to be defined and have not been addressed at the time of diagnosis of MDS. Methods: Whole exome sequencing (WES) was performed on 118 tumour and 73 paired germinal DNA from patients of 16 Spanish Group of MDS (GESMD) centers, diagnosed with de novo MDS between 16-60 years old without previous organ dysfunction. WES libraries were sequenced on a HiSeq4000-NovaSeq6000-Illumina platform, mean number of reads per sample was 144,429,985 with a Phred Quality Score &gt;30 in 94% of bases and a 100x average depth. To identify potential germline-predisposing mutations, a selection tool incorporating 279 genes associated with cause or predisposition to bone marrow failure or cancer was implemented. The analysis of the variants was carried out by means of an in house pipeline: filtering out intronic, synonymous, and those variants with minor allele frequency (MAF) in the general population &gt;1% (ExAC, 1000 Genomes-phase3, TOPmed), and requiring the presence both in tumour and germline DNA with a VAF&gt;37%. In 45 cases without germline material the last requirement was substituted by not being reported as somatic in COSMIC in any cancer. To determine pathogenicity we followed conservative criteria: a CADD Phred score ≥20 and to be considered deleterious in, at least, three out of six used algorithm. Results: In 118 patients, the median age at diagnosis was 47 years with the following WHO 2017 diagnoses: 12% MDS-SLD, 9% MDS-RS, 34% MDS-MLD, 30% MDS-EB, 3% MDS-del(5q), 1%MDS-U, 11% CMML. We found deleterious/pathogenic germ variants in 68 of 118 patients. Strikingly, we found a higher frequency than expected, for this specific subset, in genes not yet considered in the category of myeloid neoplasms with germline predisposition: MSH6 (n=5;4.2%), ATR (n=5;4.2%), ERCC6L2 (n=4;3.4%), PMS2 (n=2; 1.6%), MLH1 (n=3;3.5%), HCLS1 (n=2;1.7%), ITGB3 (n=2;1.7%), LYST (n=4; 3.4%), SAMD9 (n=1;0.8%), MSH2(n=1;0.8%). In genes already considered in the category of myeloid neoplasms with germline predisposition: MPL (n=2;1.7%), DDX41 (n= 2;1.7%), RUNX1 (n=1; 0.8%), ANKRD26 (n=1;0.8%). We also detected 10 cases with deleterious germline variants in genes related to Fanconi anemia (BRIP1, FANCC, FANCD2, FANCG, FANCM, SLX4, XRCC2, RAD51C and BRCA2), 2 cases with a germline variant in a Shwachman-Diamond gene DNAJC21 (1.7%), and 3 cases with germline variant in a telomere biology gene (RTEL1, CTC1 and TERT). We then focused on the characterization of the variants found in 5 genes not considered to date as predisposing to MDS: MSH6, MSH2, MLH1, ATR and PMS2 involved in the instability of microsatellites and whose alteration determines genomic instability and predisposition to a different number of solid tumors. The frequency of patients carrying these variants (13.5%) is much higher than the frequency of DDX41 (1.7%) or CEBPA (not found in our cohort), the two genes currently considered in the category with germline predisposition without a preexisting disorder or organ dysfunction. The sixteen patients carrying these mutations were characterized by a median age of 47 (16-60) years with the following diagnoses, 33% MDS-MLD, 27% MDS-EB1 and 40% CMML, presenting up to 40% with decrease cellularity in the bone marrow. Conclusions: We describe, for the first time, a high frequency of germinal variants in genes that drive genomic instability by modulating the microsatellite pathway, in young adults diagnosed with MDS without previous organ dysfunction. Their frequency and high pathogenicity index warrant functional validation experiments and pose them as potential candidates to be included in future classifications and to be considered in clinical, therapeutic and genetic counseling strategies. [Display omitted] Díez-Campelo:Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene Corporation: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Sanz:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Helsinn Healthcare: Membership on an entity's Board of Directors or advisory committees, Research Funding; Onconova: Membership on an entity's Board of Directors or advisory committees, Research Funding; Hoffman - La Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Boehringer-Ingelheim: Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen - Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Jerez:Novartis: Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees.</abstract><pub>Elsevier Inc</pub><doi>10.1182/blood-2019-127204</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2019-11, Vol.134 (Supplement_1), p.4226-4226
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2019_127204
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T14%3A01%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Germinal%20Predisposition%20in%20Myelodysplastic%20Syndromes%20in%20Young%20Adults%20without%20a%20Preexisting%20Disorder%20or%20Organ%20Dysfunction:%20Identification%20of%20Deleterious%20Variants%20in%20Microsatellite%20Instability%20Genes&rft.jtitle=Blood&rft.au=Chen-Liang,%20Tzu%20Hua&rft.date=2019-11-13&rft.volume=134&rft.issue=Supplement_1&rft.spage=4226&rft.epage=4226&rft.pages=4226-4226&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2019-127204&rft_dat=%3Celsevier_cross%3ES0006497118621548%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497118621548&rfr_iscdi=true